Medicinal compound and medicinal use thereof
A compound and drug technology, applied in the field of medicine, can solve problems such as low bioavailability, poor membrane permeability, and poor stability
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0232] The raw material is: salvianolic acid F;
[0233] Preparation method: add salvianolic acid F into distilled water under nitrogen protection, stir to dissolve, then filter, add saturated anhydrous potassium carbonate dropwise to the filtrate, adjust pH value, stir at room temperature, and precipitate solid. The reaction solution was filtered and dried in vacuo to obtain a yellow solid, and the following compound was obtained:
[0234]
[0235] Composing a pharmaceutical composition with the obtained compound as an active ingredient, or preparing it into a pharmaceutical preparation;
[0236] The obtained compound spectrum data are as follows:
[0237] Hydrogen spectrum (ppm): 6.86, 7.16, 7.91, 6.22, 7.12, 6.86, 6.88, 6.72, 7.16.
[0238] Carbon spectrum (ppm): 128.5, 130.2, 148.8, 146.4, 116.4, 120.3, 148.0, 115.6, 170.0, 129.2, 113.6, 147.2, 146.5, 117.2, 120.4, 137.4, 120.2.
Embodiment 2
[0240] The raw material is: salvianolic acid F;
[0241] Preparation method: take salvianolic acid F, add it to methanol, add sulfuric acid dropwise, start magnetic stirring under nitrogen protection, and heat to reflux. The reaction was detected by TLC, and the reaction solution was rotary evaporated to dryness. The residue was added to a mixture of ethyl acetate and water, and the ethyl acetate phase was separated, washed with water, dried over anhydrous magnesium sulfate, filtered, the filtrate was rotary evaporated, and purified by column chromatography. The product phase was collected and rotary evaporated to dryness to obtain a yellow solid to obtain the following compound:
[0242]
[0243] Composing a pharmaceutical composition with the obtained compound as an active ingredient, or preparing it into a pharmaceutical preparation;
[0244] The obtained compound spectrum data are as follows:
[0245] Hydrogen spectrum (ppm): 6.86, 6.99, 7.91, 6.22, 6.92, 6.86, 6.81, ...
Embodiment 3
[0248] The raw material is: salvianolic acid F;
[0249] Preparation method: add salvianolic acid F, anhydrous isopropanol, and concentrated sulfuric acid under nitrogen protection; stir and heat up, reflux occurs, and TLC detects that the reaction is complete. The reaction solution was rotary evaporated to dryness, the residue was added with ethyl acetate and water mixture, the ethyl acetate phase was separated, washed with water, dried over anhydrous sodium sulfate, filtered, the filtrate was rotary evaporated, purified by column chromatography, the product phase was collected, and spin Evaporate to dryness to obtain a pale yellow foamy solid to obtain the following compound:
[0250]
[0251] Composing a pharmaceutical composition with the obtained compound as an active ingredient, or preparing it into a pharmaceutical preparation;
[0252] The obtained compound spectrum data are as follows:
[0253] Hydrogen spectrum (ppm): 6.85, 7.13, 8.01, 6.25, 7.02, 6.84, 6.87, 6....
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More